indication

SCHIZOPHRENIA 1 (Disorder)

Competitive landscape projected to Transcranial neurostimulation’s launch window

as of 2026-07-01
Competitive set
2
2 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
35 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
2042
today
Transcranial neurostimulation launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugNot Yet Recruiting
Xanomeline-trospium (Cobenfy)
US-approved 2024 · Cobenfy
Phase 21 trial
OwnerKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Protection2039
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 21 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041

Market size

prevalence as a range, not a number